Why Nurix Therapeutics, Inc. (NRIX) stock fell 38.2% on Wednesday, November 4, 2026

Nurix Therapeutics, Inc. (NRIX) closed at $15.95, down 38.23% on Wednesday, November 4, 2026, on volume of 19,540,309 shares (10.9× its 3-month average); market value about $1.70B.

What happened: primary sources

Events Nexqual found for NRIX on Wednesday, November 4, 2026 or the trading day before (November 3, 2026):

• Nov 3, 2026: SEC 8-K: Other material event source
  Quoted from the filing: “On November 3, 2026, Nurix Therapeutics, Inc. (the " Company ") announced that collaboration partner Sanofi S.A. (" Sanofi ") had notified the Company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program. As a result of Sanofi's decision, the Company does not expect to receive any of the future development, regulatory and commercial milestone payments or royalties for which it was eligible under the Company's…”
• Nov 4, 2026: Wells Fargo: Target lowered, Equal-Weight, price target $25 → $20

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on NRIX

NRIX stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Other big moves that day: November 4, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 10, 2026 at 16:46 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 10, 2026 at 16:46 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt